問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

National Taiwan University Hospital

List

3348Cases

2015-07-10 - 2019-02-12

Phase II

A randomized phase II study of MCS110 combined with carboplatin and gemcitabine in advanced Triple Negative Breast Cancer (TNBC)

  • Condition/Disease

    advanced Triple Negative Breast Cancer (TNBC)

  • Test Drug

    MCS110

Participate Sites
1Sites

Terminated1Sites

2017-05-01 - 2020-12-31

Phase I

A phase I/Ib, open-label, multi-center dose escalation study of NIS793 in combination with PDR001 in adult patients with advanced malignancies

  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    NIS793, PDR001

Participate Sites
1Sites

Terminated1Sites

2017-03-31 - 2022-07-01

Phase II/III

Multicenter, open-label, study to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of LCZ696 followed by a 52-week randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to enalapril in pediatric patients from 1 month to < 18 years of age with heart failure due to systemic left ventricle systolic dysfunction.

  • Condition/Disease

    pediatric patients with heart failure due to systemic left ventricle systolic dysfunction.

  • Test Drug

    LCZ696

Participate Sites
3Sites

Recruiting3Sites

2016-11-01 - 2021-04-10

Phase III

A multi-center, randomized, double-blind, active-controlled, parallel-group Phase 3 study to evaluate the efficacy and safety of LCZ696 compared to ramipril on morbidity and mortality in high risk patients following an acute myocardial infarction

  • Condition/Disease

    acute myocardial infarction

  • Test Drug

    LCZ696

Participate Sites
9Sites

Not yet recruiting2Sites

Terminated7Sites

2017-01-01 - 2021-11-17

Phase III

A phase III randomized open-label multi-center study of ruxolitinib versus best available therapy in patients with corticosteroid-refractory acute graft vs. host disease after allogeneic stem cell transplantation

  • Condition/Disease

    Corticosteroid Refractory Acute Graft vs Host Disease

  • Test Drug

    INC424

Participate Sites
3Sites

Terminated2Sites

2016-07-01 - 2020-01-31

Others

A randomized, double-blind, placebo controlled, 2- part, adaptive design, multicenter 12-week study to assess safety, tolerability and efficacy of LJN452 in patients with non-alcoholic steatohepatitis (NASH)

  • Condition/Disease

    non-alcoholic steatohepatitis (NASH)

  • Test Drug

    LJN452 (tropifexor)

Participate Sites
8Sites

Terminated6Sites

黃志富
Kaohsiung Municipal Gangshan Hospital

未分科

黃怡翔
Taipei Veterans General Hospital

Digestive System Department

2013-07-30 - 2015-11-30

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2013-07-09 - 2024-01-07

Phase III

A phase III multicenter, randomized study of oral LDK378 versus standard chemotherapy in previously untreated adult patients with ALK rearranged (ALK-positive), stage IIIB or IV, non-squamous non-small cell lung cancer

  • Condition/Disease

    Non small cell lung cancer

  • Test Drug

    LDK378

Participate Sites
7Sites

Terminated7Sites

2013-09-10 - 2015-10-31

Phase III

A 52-week treatment, multi-center, randomized, doubleblind, double dummy, parallel-group, active controlled study to compare the effect of QVA149 (indacaterol maleate / glycopyrronium bromide) with salmeterol/fluticasone on the rate of exacerbations in subjects with moderate to very severe COPD

  • Condition/Disease

    moderate to very severe COPD

  • Test Drug

    QVA149

Participate Sites
8Sites

Terminated7Sites

Study ended1Sites

徐武輝
China Medical University Hospital

Division of Thoracic Medicine

2014-04-01 - 2019-12-31

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

1 294 295 296 297 298 335
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB